Pegfilgrastim Biosimilar Market

Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market. Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.
Pegfilgrastim Biosimilar Market contains market size and forecasts of Pegfilgrastim Biosimilar in global, including the following market information:
Global Pegfilgrastim Biosimilar Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Pegfilgrastim Biosimilar Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Pegfilgrastim Biosimilar companies in 2021 (%)
The global Pegfilgrastim Biosimilar market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Chemotherapy Treatment Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Pegfilgrastim Biosimilar include Novartis, Mylan, Coherus BioSciences, Mundipharma International, Biocon, Intas Pharmaceuticals, Pfizer and Dr Reddy?s Laboratories, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Pegfilgrastim Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Pegfilgrastim Biosimilar Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pegfilgrastim Biosimilar Market Segment Percentages, by Type, 2021 (%)
Chemotherapy Treatment
Transplantation
Global Pegfilgrastim Biosimilar Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pegfilgrastim Biosimilar Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Mail-Order Pharmacies
Retail Pharmacies
Global Pegfilgrastim Biosimilar Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Pegfilgrastim Biosimilar Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Pegfilgrastim Biosimilar revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Pegfilgrastim Biosimilar revenues share in global market, 2021 (%)
Key companies Pegfilgrastim Biosimilar sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Pegfilgrastim Biosimilar sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Novartis
Mylan
Coherus BioSciences
Mundipharma International
Biocon
Intas Pharmaceuticals
Pfizer
Dr Reddy?s Laboratories